- BMS, Pfizer work together on Phase III antithrombotic
- BMS joins Sterling, Sanofi on heart projects; agreement later revised
- Pfizer gives BMS rights to early-stage metabolic projects
- BMS, Merck develop muraglitazar for diabetes: terminated
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
- Portola gets $70mm through its Series C venture round; adds $60mm
- BMS gets rights to Isis' antisense cholesterol reducers; ended
- Sanofi-Aventis, BMS, Apotex in deal to settle Plavix suit
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.